- /
- Supported exchanges
- / US
- / VRXA.NASDAQ
Veraxa Biotech AG Ordinary Shares (VRXA NASDAQ) stock market data APIs
Veraxa Biotech AG Ordinary Shares Financial Data Overview
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Veraxa Biotech AG Ordinary Shares data using free add-ons & libraries
Get Veraxa Biotech AG Ordinary Shares Fundamental Data
Veraxa Biotech AG Ordinary Shares Fundamental data includes:
- Net Revenue: 23 426
- EBITDA: -64 244 176
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Veraxa Biotech AG Ordinary Shares Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Veraxa Biotech AG Ordinary Shares News
New
This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading
VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered the NASDA...
VERAXA Biotech Designates Raju Willener as CFO
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before b...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.